Acta Scientific Ophthalmology (ISSN: 2582-3191)

Case Report Volume 6 Issue 3

Best's Disease: Diagnostic Criteria and Antiangiogenic Therapy Efficacy - A Case Report

Andrey Kopylov* and Anna Korolenko

Pediatric Ophthalmology Department, Irkutsk Branch of S.N. Fyodorov "Eye Microsurgery" Federal State Institution, Ministry of Health of Russian Federation, Russia

*Corresponding Author: Andrey Kopylov, Pediatric Ophthalmology Department, Irkutsk Branch of S.N. Fyodorov "Eye Microsurgery" Federal State Institution, Ministry of Health of Russian Federation, Russia.

Received: June 29, 2022; Published: February 06, 2023


Purpose: To present a case report of diagnosis and management of a child’s macular neovascularization (MNV) associated with Best's vitelliform macular dystrophy.

Material and Methods: A 15-year-old patient with decreased vision in both eyes (more left than right). The vision decrease was first detected during an examination, including the determination of the best corrected visual acuity (BCVA), the vision field, and the collection of a genealogical history; OCT and OCTA revealed macular degeneration and active MNV.

Results and Discussion: Stabilization of the pathological process in the form of adhering of the neuroepithelium detachment over the MNV was achieved only in the right eye after the 1st ranibizumab injection. Relapses and continued activity of newly formed vessels were noted in the left eye.

The lack of sufficient suppression of de novo vessels can be explained by 1 MNV type, deposition of lipofuscin-like material and presence of a large adductor vessel - a branch of the posterior short ciliary artery, which in general are prognostically unfavorable factors determining possible relapses and progression of pathological retinal changes. At the same time, during the natural disease course, the vitelliform material was displaced by gravity into the lower segments of the macular region and its further resorption, while the active adductor vessel was preserved.

Conclusion: Kids’ diagnosis of Best's vitelliform macular dystrophy is based on a complex of studies, including the collection of genealogical history, OCT, OCTA, autofluorescence. It is possible to verify the disease at early stages of the pathological process, to conduct timely therapy and adequate monitoring with an assessment of the activity degree of newly formed vessels and structural retinal changes. The key factors determining the need for antiangiogenic therapy in children with Best's disease are not only the active form of MNV, but also structural retinal changes and the state of visual functions.

Keywords: Best's Disease; Macular Neovascularization (MNV); Vitelliform Macular Dystrophy; Bestrophin; Antiangiogenic Therapy


  1. Shcherbatova OI and Mosin IM. “Best's disease and vitelliform dystrophy of adults”. In the book: Shamshinova A.M., ed. Hereditary and congenital diseases of the retina and optic nerve. M.: Medicine; (2001).
  2. Kovalevskaya MA., et al. “Combined functional diagnostics of best dystrophy”. Clinical Ophthalmology 13.4 (2013): 181-184.
  3. Katargina LA., et al. “Best disease: clinical observation of a family case”. Russian Pediatric Ophthalmology 2 (2015): 15-19.
  4. Johnson AA., et al. “Bestrophin 1 and retinal disease”. Progress in Retinal and Eye Research 58 (2017): 45-69.
  5. Hereditary retinal dystrophy. Clinical recommendations (2021).
  6. Small KW., et al. “Best Vitelliform Macular Dystrophy (BVMD) is a phenocopy of North Carolina Macular Dystrophy (NCMD/MCDR1)”. Ophthalmic Genetics (2021): 1-11.
  7. Miyagi M., et al. “Clinical findings in eyes with BEST1-related retinopathy complicated by choroidal neovascularization”. Graefe's Archive for Clinical and Experimental Ophthalmology 4 (2022): 1125-1137.
  8. Parodi MB., et al. “Optical Coherence Tomography Angiography Quantitative Assessment of Macular Neovascularization in Best Vitelliform Macular Dystrophy”. Investigative Ophthalmology and Visual Science 6 (2020): 61.
  9. Jarc-Vidmar M., et al. “Intravitreal bevacizumab treatment for exudative choroidal neovascularisation in best vitelliform macular dystrophy”. European Journal of Ophthalmology (2021).
  10. Chhablani J and Jalali S. “Intravitreal bevacizumab for choroidal neovascularization secondary to Best vitelliform macular dystrophy in a 6-year-old child”. European Journal of Ophthalmology 4 (2012): 677-679.
  11. Hussain RN., et al. “Use of intravitreal bevacizumab in a 9-year-old child with choroidal neovascularization associated with autosomal recessive bestrophinopathy”. Ophthalmic Genetics 3 (2015): 265-269.
  12. Cennamo G., et al. “Functional and Anatomic Changes in Bilateral Choroidal Neovascularization Associated with Vitelliform Macular Dystrophy After Intravitreal Bevacizumab”. Journal of Ocular Pharmacology and Therapeutics 6 (2012): 643-646.
  13. Khan KN., et al. “Functional and anatomical outcomes of choroidal neovascularization complicating BEST1-related retinopathy”. Retina 7 (2017): 1360-1370.
  14. Elkhoyaali A., et al. “Choroidal neovascularization complicating Best's vitelliform macular dystrophy in a child”. Journal Français D'ophtalmologie 1 (2016): 69-73.
  15. Arrigo A., et al. “Macular neovascularization in AMD, CSC and best vitelliform macular dystrophy: quantitative OCTA detects distinct clinical entities”. Eye (Lond) 12 (2021): 3266-3276.
  16. Heidary F., et al. “Intravitreal Ranibizumab for Choroidal Neovascularization in Best's Vitelliform Macular Dystrophy in a 6-Year-Old Boy”. Journal of Pediatric Ophthalmology and Strabismus (2011): 48 Online:e19-22.
  17. Ozdek S., et al. “Photodynamic therapy for best disease complicated by choroidal neovascularization in children”. Journal of Pediatric Ophthalmology and Strabismus 4 (2012): 216-221.
  18. Frennesson ChI., et al. “Best vitelliform macular dystrophy in a Swedish family: genetic analysis and a seven-year follow-up of photodynamic treatment of a young boy with choroidal neovascularization”. Acta Ophthalmology3 (2014): 238-242.
  19. de Souza CPR., et al. “Best vitelliform macular dystrophy in a large Brazilian family”. International Journal of Retina and Vitreous 5 (2019).
  20. Menteş J and Barış ME. “Multimodal Imaging Characteristics of Quiescent Type 1 Neovascularization in Best Vitelliform Macular Dystrophy”. Turkish Journal of Ophthalmology3 (2021): 188-191.
  21. Shahzad R., et al. “Choroidal neovascularization secondary to Best vitelliform macular dystrophy detected by optical coherence tomography angiography”. Journal of AAPOS 1 (2017): 68-70.
  22. White RJ., et al. “Association of Optic Nerve Head Drusen with Best Vitelliform Macular Dystrophy: A Case Series”. Case Reports in Ophthalmology 1 (2018): 76-86.
  23. Oleshchenko IG., et al. “Wing-healing blockade in ophthalmic surgery”. In the book: Topical issues of improving anesthesiological and resuscitation care in the Russian Federation: a book of abstracts (2018): 157-158.
  24. Oleshchenko IG., et al. “Influence of the spheropalatine blockade on the change in oxidation-reduction potential in the surgical treatment of congenital cataract”. Siberian Scientific Medical Journal 5 (2018): 72-78.
  25. Mirshahi A., et al. “Optical coherence tomography angiography in best vitelliform macular dystrophy”. Journal of Current Ophthalmology4 (2019): 442-445.
  26. Parodi MB., et al. “Natural course of the vitelliform stage in best vitelliform macular dystrophy: a five-year follow-up study”. Graefe's Archive for Clinical and Experimental Ophthalmology2 (2020): 297-301.


Citation: Andrey Kopylov and Anna Korolenko. “Best's Disease: Diagnostic Criteria and Antiangiogenic Therapy Efficacy - A Case Report".Acta Scientific Ophthalmology 6.3 (2023): 07-13.


Copyright: © 2022 Andrey Kopylov and Anna Korolenko. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate35%
Acceptance to publication20-30 days
ISI- IF1.042
JCR- IF0.24

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US